Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT) will announce its second quarter 2022 financial results on August 2, 2022, after market close. A conference call to discuss these results and provide a corporate update will follow at 4:30 p.m. E.T. The event will be available via live webcast on Sarepta's investor relations website. Sarepta is a leader in precision genetic medicine, focusing on rare diseases, with over 40 programs in development, particularly for Duchenne muscular dystrophy and limb-girdle muscular dystrophies.

Positive

• Sarepta is a leader in precision genetic medicine for rare diseases.
• More than 40 programs in various stages of development.
• Focus on Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs).

Negative

• None.

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2022 financial results and to provide a corporate update.

The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

FAQ

When will Sarepta Therapeutics report its Q2 2022 financial results?

Sarepta Therapeutics will report its Q2 2022 financial results on August 2, 2022, after the market closes.

What time is the Sarepta conference call on August 2, 2022?

The conference call will begin at 4:30 p.m. E.T. on August 2, 2022.

How can I listen to Sarepta's financial results conference call?

The conference call can be listened to via live webcast on Sarepta's investor relations website.

What diseases does Sarepta Therapeutics focus on?

Sarepta Therapeutics focuses on rare diseases, primarily Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs).

How many programs is Sarepta currently developing?

Sarepta has more than 40 programs in various stages of development.